Literature DB >> 12054629

ADAMTS1 cleaves aggrecan at multiple sites and is differentially inhibited by metalloproteinase inhibitors.

Juan Carlos Rodríguez-Manzaneque1, Jennifer Westling, Shelley N-M Thai, Alfonso Luque, Vera Knauper, Gillian Murphy, John D Sandy, M Luisa Iruela-Arispe.   

Abstract

ADAMTS1 is a secreted protein that belongs to the recently described ADAMTS (a disintegrin and metalloprotease with thrombospondin repeats) family of proteases. Evaluation of ADAMTS1 catalytic activity on a panel of extracellular matrix proteins showed a restrictive substrate specificity which includes some proteoglycans. Our results demonstrated that human ADAMTS1 cleaves aggrecan at a previously shown site by its mouse homolog, but we have also identified additional cleavage sites that ultimately confirm the classification of this protease as an 'aggrecanase'. Specificity of ADAMTS1 activity was further verified when a point mutation in the zinc-binding domain abolished its catalytic effects, and latency conferred by the prodomain was also demonstrated using a furin cleavage site mutant. Suppression of ADAMTS1 activity was accomplished with a specific monoclonal antibody and some metalloprotease inhibitors, including tissue inhibitor of metalloproteinases 2 and 3. Finally, we developed an activity assay using an artificial peptide substrate based on the interglobular domain cleavage site (E(373)-A) of rat aggrecan.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12054629     DOI: 10.1016/S0006-291X(02)00254-1

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  79 in total

1.  Variations in aggrecan structure modulate its susceptibility to aggrecanases.

Authors:  Peter J Roughley; James Barnett; Fengrong Zuo; John S Mort
Journal:  Biochem J       Date:  2003-10-01       Impact factor: 3.857

Review 2.  ADAMTS proteases: key roles in atherosclerosis?

Authors:  Rebecca C Salter; Tim G Ashlin; Alvin P L Kwan; Dipak P Ramji
Journal:  J Mol Med (Berl)       Date:  2010-07-22       Impact factor: 4.599

Review 3.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

4.  The ADAMTS13 metalloprotease domain: roles of subsites in enzyme activity and specificity.

Authors:  Rens de Groot; David A Lane; James T B Crawley
Journal:  Blood       Date:  2010-07-20       Impact factor: 22.113

5.  ADAMTS13 and 15 are not regulated by the full length and N-terminal domain forms of TIMP-1, -2, -3 and -4.

Authors:  Cenqi Guo; Anastasia Tsigkou; Meng Huee Lee
Journal:  Biomed Rep       Date:  2015-10-30

6.  Over-expression of Adamts1 in mice alters bone mineral density.

Authors:  Lijuan Hu; Kenneth B Jonsson; Harriet Andersén; Anne Edenro; Mohammad Bohlooly-Y; Håkan Melhus; Thomas Lind
Journal:  J Bone Miner Metab       Date:  2011-10-15       Impact factor: 2.626

Review 7.  Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.

Authors:  Xi Wang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2017-09-19

8.  The ADAMTS1 protease gene is required for mammary tumor growth and metastasis.

Authors:  Carmela Ricciardelli; Kate M Frewin; Izza de Arao Tan; Elizabeth D Williams; Kenneth Opeskin; Melanie A Pritchard; Wendy V Ingman; Darryl L Russell
Journal:  Am J Pathol       Date:  2011-10-12       Impact factor: 4.307

9.  Endothelial deletion of murine Jag1 leads to valve calcification and congenital heart defects associated with Alagille syndrome.

Authors:  Jennifer J Hofmann; Anais Briot; Josephine Enciso; Ann C Zovein; Shuxun Ren; Zhen W Zhang; Freddy Radtke; Michael Simons; Yibin Wang; M Luisa Iruela-Arispe
Journal:  Development       Date:  2012-10-24       Impact factor: 6.868

Review 10.  The roles of ADAMTS in angiogenesis and cancer.

Authors:  Yi Sun; Jintuan Huang; Zuli Yang
Journal:  Tumour Biol       Date:  2015-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.